Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thalidomide - Celgene Corporation

Drug Profile

Thalidomide - Celgene Corporation

Alternative Names: Alpha-N-phthalimidoglutarimide; CC-2001; FPF-300; K-17; NSC-66847; Synovir; Thaled; Thalidomide Celgene; Thalidomide Pharmion; Thalomid

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EntreMed; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); University of Pennsylvania
  • Developer Celgene Corporation; Erkim; Fujimoto Pharmaceutical; Laphal; Weill Cornell Medical College
  • Class Antileprotics; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Cachexia; Multiple myeloma; Aphthous stomatitis; Crohn's disease; Leprosy; Kaposi's sarcoma; Mycobacterial infections; Myelodysplastic syndromes; Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy; Multiple myeloma
  • Phase II Waldenstrom's macroglobulinaemia
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 02 Jul 2019 No development reported - Preregistration for Leprosy in Hong Kong (PO)
  • 02 Jul 2019 No development reported - Preregistration for Multiple myeloma in Hong Kong (PO)
  • 18 Dec 2018 Celgene completes an expanded-access programme in USA (PO) (NCT03723083)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top